StemCell Therapy

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

Read the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

Go here to read the rest:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

Pharmaceutical stocks, which have seen temporary spikes during the coronavirus crisis as investors bet on the possibility of a vaccine, may be getting ahead of themselves.

Markets are speculating that some products may prove instrumental in the fight against the deadly disease, which has infected thousands in China, left 200 dead and rattled global markets.

However, biotech experts say that buyers should certainly be wary of trying to trade on coronavirus fears, given that most companies lack an established track record or are simply trying to position themselves to benefit from public health crisis.

Theres two things that biotech companies, especially small ones, are always looking for: Attention and cash, Brad Loncar, a biotech investor, told Yahoo Finance on Friday.

And, sadly, a lot of them take advantage of situations...putting out a press release saying they are working on something and you see their stocks zoom, Loncar added.

To be sure, not all pharma companies are created equal. To fight the coronavirus, large cap companies like Johnson & Johnson (JNJ), AbbVie (ABBV) and Gilead Sciences (GILD) announced they were repurposing HIV, Ebola and Zika products that had been developed but are not on the market to create a vaccine. Separately, Roche is planning to disseminate testing kits for the virus.

Meanwhile, China and Hong Kongs biotech companies may hold more promise for finding a treatment or cure, amid a rise of domestic Chinese companies competing with U.S. or European brands.

A lot of people dont know theres a biotech boom happening in China today, according to Loncar, who manages a Chinese biotech exchange-traded fund. Its an example that China can rise to this call.

People wear face masks and walk at a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. People wear face masks as they walk through a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. According to the Taiwan Centers of Disease Control (CDC) Friday, the tenth case diagnosed with the new coronavirus has been confirmed in Taiwan. (AP Photo/Chiang Ying-ying)

Yet finding effective treatments and cures for the virus is easier said than done. It took five years for the first Ebola vaccine to hit the market, and the coronavirus vaccine is likely to follow the same pattern.

Barring a dramatic breakthrough, it means the sickness could rage for an extended period before a solution is found which means investors should be particularly careful about sinking money into biotech and pharma companies making big promises.

That includes stocks of smaller companies, which saw fleeting rallies last week on vaccine speculation. Inovio (INO), Moderna (MRNA), Novavax (NVAX), Meridian Biosciences (VIVO), Vir Biotechnology (VIR) and BioCryst (BCRX). Virtually all of them have pared or completely reversed the weeks initial gains.

Its important to know how big the potential universe for any vaccine is likely to be, Chris Meekins, a biotech analyst, told Yahoo Finance this week.

So companies that have a partnership with the government those would be areas that are better to invest in than companies that dont have government funding, because I dont believe theres a sustained investment, he added.

Robert W. Baird research analyst Brian Skorney told Yahoo Finance the companies who do end up making something are likely not to make any money either.

It is really unlikely that anyone is going to get paid for product that even does treat coronavirus, Skorney said. its not going to be something that companies are going to be able to generate a substantial profit, he said.

Read the original:
Biotech stocks get a boost from coronavirus fears -- but here's why investors should be wary - Yahoo Finance

Halozyme Therapeutics, Inc. (HALO) is near the top in its industry group according to InvestorsObserver. HALO gets an overall rating of 54. That means it scores higher than 54 percent of stocks. Halozyme Therapeutics, Inc. gets a 60 rank in the Biotechnology industry. Biotechnology is number 51 out of 148 industries.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $20.83 as of 10:15 AM on Wednesday, Feb 5, a rise of $1.53, or 7.9% from the previous closing price of $19.30. The stock has traded between $20.06 and $21.28 so far today. Volume today is low. So far 663,847 shares have traded compared to average volume of 1,434,881 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology - InvestorsObserver

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

Originally posted here:
Where Is The Biotech Market Heading? - CIO Applications

The Overview for Agricultural Biotechnology Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 20202029

We at MarketResearch.biz will help your business by providing the latest market reports containing all the data required to capture opportunities while increasing effectiveness. The report on Agricultural Biotechnology Market has been prepared with the help of modern analytical techniques such as SWOT Analysis and PESTLE Analysis which not only covers the technical areas but also the political and ecological factors that are affecting the market. Our report will help by providing a calculated forecast so as to make business aware of incoming possible opportunities and or problems.

Leading Market players like KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. have been maintaining their position in the Global Agricultural Biotechnology market with the help of their up-to-date knowledge and readily available data to make an informed decision to effectively act on any opportunities that present itself.

***Access FREE PDF Sample Copy of the Report(Contains- Keyplayers, Growth Value, Segments, etc)! Click here***

Various classifications have been applied to the data to make it more readable to suit the eyes of a businessman. Following are some of the classifications provided in the report;

By Application:Vaccine DevelopmentTransgenic Crops and AnimalsAntibiotic DevelopmentNutritional SupplementsFlower CulturingBiofuels

By Organism Type:PlantsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesAnimalsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesMicrobesConventional TechniquesEstablished Genetic ModificationNew Breeding Techniques

Regional Analysis:

1. North America (United States, Canada)

2. Europe (Germany, Spain, France, UK, Russia, and Italy)

3. Asia-Pacific (China, Japan, India, Australia, and South Korea)

4. Latin America (Brazil, Mexico, etc.)

5. The Middle East and Africa (GCC and South Africa)

Available Array of Customizations:

Country-level bifurcation of data in terms of Type and Application for any specific country/countries.

Expansion of scope and data forecasts until 2029

Company Market Share for specific country/countries and regions

Customized Report Framework for Go-To-Market Strategy

Customized Report Framework for Merger & Acquisitions and Partnerships/JVs Feasibility

Customized Report Framework for New Product/Service Launch and/or Expansion

Any other Miscellaneous requirements with feasibility analysis

*****Any query?Inquire/Share Your Questions HereOr Report Customization*****

Which prime data figures are included in the report?

-Market size (Last few years, current and expected)

-Market share analysis as per different companies

-Market forecast

-Demand

-Price Analysis

-Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report?

-Market Investigators

-Teams, departments, and companies

-Competitive organizations

-Individual professionals

-Vendors, Buyers, Suppliers

What are the crucial aspects incorporated in the report?

-Industry Value Chain

-Consumption Data

-Market Size Expansion

-Key Economic Indicators

In this study, the years considered to estimate the market size of the Agricultural Biotechnology are as follows:

Base Year:2019 | Estimated Year:2020 | Forecast Year: 2020 to 2029

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

The report caters to the subsequent questions pertaining To the Agricultural Biotechnology market:

Which Regional market is very likely to witness the maximum growth in terms of talk and value?

What Are the latest trends in the sector that is Agricultural Biotechnology?

What Is the forecasted value of this Agricultural Biotechnology economy in 2019?

Which End-use is likely to gain significant traction?

How Have advancements impacted the production procedures of this Agricultural Biotechnology in the last several years?

Purposes Behind Buying Agricultural Biotechnology Report:-

-> This report gives a stick direct examination toward changing focused elements.

-> It gives a forward-looking perspective on changed elements producing or restricting business sector improvement.

-> It gives a five-year evaluation surveyed based on how the market is anticipated to develop.

-> It helps in understanding the essential part sections and their prospect.

-> It gives stick point investigation of changing competition components and keeps you in front of contenders.

-> It helps in settling on educated business decisions by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

The Agricultural Biotechnology Market report concludes with sharing vital report findings with readers. Here on the basis of the study of historical data, the examination of the current scenarios overserved in various markets including regional and domestic and trends recorded, it delivers a forecast of the market. This includes segmental forecast, market size forecast, regional market forecast, consumption forecast.

Why Pick Marketresearch.biz?

Systematic Market research procedure

Data Gathered from credible and dependable secondary and primary resources

Team Of highly trained and skilled analysts with a profound comprehension of the most recent market research methods

Swift and efficient ordering process

Round the clock customer support catering to inquiries from global and domestic Customers

TO Download Detailed TOC ofAgricultural Biotechnology Market@https://marketresearch.biz/report/agricultural-biotechnology-market/#toc

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Thanks a million for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest.

See the original post here:
Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - TheLoop21

Vir Biotechnology (VIR) Stock Volatility Indicators To Watch:

Volatility of the Vir Biotechnology remained at 23.33% over last week and shows 11.80% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 2.71.

Vir Biotechnology (VIR) has a market capitalization of $2.21B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock declined -14.36% to value at $22.81 on Monday trading session. VIR recorded volume of 1199133 shares in most recent trading session as compared to an average volume of 268.65K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. The stock EPS is $-1.26 against its recent stock value of $22.81 per share.

Looking into the Profitability indicators on Vir Biotechnology stock we analyze the stocks Profitability ratios.

Profitability Spotlight for Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -7.95% during the period of last 5 trading days. The stock maintained for the month at 87.70%. The stock noted year to date 2019 performance at 81.35% and changed about 61.74% over the last three months. The stock is now standing at -21.36% from 52 week-high and is situated at 95.74% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 63.39.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently up 34.32% from its 20 days moving average and trading 58.72% up the 50 days moving average. The stock price has been seen performing along above drift from its 200 days moving average with 59.36%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Read the original here:
Look Vir Biotechnology (VIR) Stock Where Its Heading? - News Welcome

The following is a roundup of top developments in the biotech space over the last 24 hours:

(Biotech stocks that hit 52-week highsFeb. 5.)

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More here:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Benzinga

In January, Germany joined the EU's "1+ Million Genomes Initiative". While the German government had previously declined to actively participate in the project and Germany had merely assumed the role of an observer, it can now become involved in sharing genome data across Europe for research purposes. Genome analysis is not only instrumental to the future diagnosis, prevention and treatment of rare diseases, it is also an important economic factor in digital health.

1. GENOME SEQUENCING

Human genomes are made up of at least 20,000 genes containing all our genetic information. Genome sequencing allows us to decode almost all mutations in human genomes. This enables us to identify individual gene defects causing diseases and thus to better diagnose and treat rare diseases. Increasingly, whole genome sequencing is being used in the field of tumours to identify mutations and tailor medication to the genetic makeup of a specific tumour.

But although the development of new technologies such as high throughput DNA sequencing over recent years has made it much easier and faster to carry out human genome research, the mutations that cause disease have been determined only for around 4,000 of the 20,000 protein-coding human genes. Medical researchers will probably need decades to identify all genetic causes of disease.

2. THE EU'S GENOME INITIATIVE: 1 MILLION GENOMES BY 2022

In order to produce reliable scientific findings, researchers need broad access to genomic data from both healthy and sick patients. The aim of the EU's Genome Initiative is to collect at least one million sets of genomic data by 2022 and make these accessible beyond EU borders. The initiative is part of the EU's agenda for the digital transformation of health and care, which is aimed at harnessing the potential of new digital technologies to improve healthcare. In a declaration published in April 2018, EU, EEA and EFTA countries agreed to work together to build up and link genome databases to form a suitable technical infrastructure. So far, 21 EU member states and Norway have signed the declaration. Ten specialised working groups have been set up to look into ethical, legal and social issues, common data standards, best practices for sequencing, issues relating to health economics, research and public sector participation, as well as to analyse uses for rare diseases, cancer and common complex diseases.

3. CURRENT LEGAL SITUATION IN GERMANY

The current market leaders in genome analysis are the USA, China, the UK and some EU member states from Continental Europe. While other countries have already introduced whole genome sequencing as a standard procedure in genetic diagnostics and have produced millions of sets of data, Germany has only generated tens of thousands of data sets from whole genome sequencing. This cautious approach was put down to the particularly high level of interoperability required and restrictions due to data protection regulations.

There are certainly still some legal and also financial obstacles to be overcome in Germany. Although the German Genetic Diagnostics Act (Gendiagnostikgesetz, "GDA") provides a legal framework for genome sequencing for medical purposes and establishing parenthood, there is no specific legislation governing genome analysis for research purposes.

Genetic Diagnostics Act on genome analysis for medical purposes and establishing parenthood

Genome analysis for medical purposes entails diagnostic and predicative genetic testing. Like genome analysis to establish parenthood, it is governed by the GDA. It stipulates that doctors have to provide genetic advice, restricts genome testing and analysis to doctors with appropriate training and provides for a patient's right "not to know" the results. Moreover, according to the GDA, patients must be given comprehensive information on the procedure beforehand and they must grant their consent.

Genome sequencing has already become part of standard care in Germany and since mid-2016 has been included in the German physicians' fee schedule. However, unlike in England, the German system does not cover sequencing of whole genomes but only of a very small gene panel of up to 25 kilobases, which corresponds to an average of four genes. For some diseases, up to 1,000 genes need to be analysed. Doctors wishing to perform larger sequencing projects have to apply for extra-budgetary services. Since such applications have often been rejected in the past due to the strict requirements, there is currently no incentive for physicians to perform medical genome analysis.

Pursuant to the GDA, genetic testing to establish parenthood requires the consent of the individuals providing the samples and can also be performed by specialists not qualified as doctors, for instance molecular biologists. Unlike in the USA, for example, analyses performed privately are not permissible.

No specific legislation on genome analysis for research purposes

The German legislator deliberately decided not to extend the scope of the GDA to cover genome analysis for research purposes, including general research on the factors affecting human characteristics. By contrast to predictive genetic testing, such research is not aimed at developing specific treatment for specific individuals. This means there are no specific regulations in this field of research, so the general statutory provisions apply.

Therefore, for related clinical studies, the general German laws on medicinal products and medical devices apply. They require that participants be provided with full information on any testing and must grant their prior consent. Since genome analysis involves collecting personal data, the General Data Protection Regulation (GDPR) and national data protection regulations also apply. Article 9 of the GDPR classifies genetic data as sensitive data that may only be processed if the data subject has given their explicit consent or with special legal permission. However, the German legislator took advantage of the exemption clauses in Article 89 (2) GDPR. Article 89 states that genetic data may be processed for scientific research purposes even without consent if it would otherwise be impossible to fulfil such purposes and the interests of the party responsible for processing the data significantly outweigh the interests of the data subject in not having data processed. Given the significance of genome sequencing for research, the consent requirement could therefore be dispensed under data protection regulations.

However, this would breach the strict laws on medicinal products and medical devices which require consent to the use of data in clinical studies. Data protection law also entitles data subjects to request information on their data or have their data deleted. This may be difficult to put into practice if large amounts of data have been collected. Another point to be clarified is whether individuals have a right to know or not to know about random genetic findings.

Ultimately, in the absence of specific legislation on genome analysis for research purposes, many legal questions have yet to be answered. It remains to be seen whether the legislator will set out more precise regulations in future.

4. WHERE DO WE GO FROM HERE?

The Federal Ministry of Research (Bundesforschungsministerium) has announced that the next step will be to set up national working groups. A detailed schedule and set of requirements are to be drawn up by mid-2021. Only then will it be possible to develop strategies for the cross-border use of genomic and phenotypic data. According to the Ministry, the first locations for testing the secure sharing of genomic data are to be selected by the end of 2020. On that basis, it will be possible to donate genomes during clinical treatment.

By joining the Genome Initiative, Germany has taken an important step in terms of digital health. Now the task is to adjust the existing legal framework to cover whole genome sequencing and to clarify the remaining legal issues. In future, genome analysis will play a key role not only for major pharmaceutical companies, manufacturers of medical devices, hospitals and research institutes, which are directly or indirectly involved in researching rare diseases, but also for investors. To meet today's legal and regulatory challenges and any further challenges the future may bring, all players will have to keep a close eye on developments in this field.

Follow this link:
Germany Joins the Genomes Initiative - Lexology

Editor's note:This article is part of Inc.'s 2020 Best Industries report.

"I love my family, but that's ridiculous," Glover says.

That same year, Glover co-founded120 Water Audit to develop more affordable consumer water testing kits. Now the company also tests and manages drinking water programsfor government agencies, public water systems, schools, and other facilities.120 Water Audit is a leader among a growing group of startups serving utility companies and government agencies that have been forced to update systems and respond togrowing consumer concerns in the wake of crises like Flint.

Turning on the tap

Glover, a former marketing and business development executive, launched 120 Water Audit with co-foundersChris Baggott and Dave Kohl.(Baggott and Kohl were never operational with the company, but Baggott is on the board of directors.) They initially bootstrapped the business and worked out of Glover's parents' garageuntil the company won its first contracts with the city ofPittsburgh, the state of Indiana, andutilities in Loveland, Colorado, and Lewisville, Texas.

To collect samples, the startup sends water bottles that customers fill from the source they wish to test.Each bottle comes with a prepaid return envelope that goes to an EPA-certified lab for testing. Individual water tests rangefrom $54 to $84, depending on the type of analysis. Meanwhile, the company's software helpsclientsaggregate data and automate tasks like sending recurring reports.

120 Water Audit's tests detecttoxins like lead, copper, and arsenic, whichat certain levels have been linked to learning problemsamong children, reproductive issues, and, in rare cases, death, according to the Environmental Protection Agency. Some of these contaminants occur naturally, while othersmake their way into water supplies from manufacturing facilities orinfrastructure failuressuch asold pipes. The Flint water crisis is one of the most recent instances of the latter: The city switched its water source in 2014;officials failed to treat the water and lead from older pipes seeped in.Some residents experienced lead poisoning, while low chlorine levels led to a deadly outbreak of Legionnaire's disease.

The Flint crisis raised consumer awareness of drinking water safety, and as a result,120 Water Audit has seen a steady risein sales since its launch. The company--named for the frequency it believes consumers should test their water, which is every 120 days--booked $3.3 million in revenue last year, up from about $2 million in 2018. Glover declined to share whether the company was profitable.

A flood of activity

Glover's startup isn't the only one to see an increase in activity: Last year, businesses working on clean water initiatives--which tackle a broad array of services, including producing drinkable water from new sources and real-time water monitoring--raised $50.7 million in venture capital funding, according to the data and research company PitchBook. That's a $10.9 million increase from 2014, but it's stilla relatively low amount of VC funding for an entire industry.

120 Water Audit wasone of the best-funded startups in the industry last year: It raised $7 million in venture capital, which makes up 13.8 percent of theindustry's totalventure capital dollars from last year, according to Pitchbook. In total, the company has raised $9.4 million, including a$100,000 first prize from former America Online CEO Steve Case's Rise of the Rest pitch competition. Glovercredits a majority of 120 Water Audit's growth to newly implemented drinking water regulations and stricter water quality specifications in the wake of Flint.

"Consumers are getting a lot more vocal about the quality of their water," she says. "That's forcing [traditional water utility companies] to think differently about the programs they run and how they communicate with consumers."

Crises like Flintare leading consumers to take action by using theseservices or pushing government agencies for more testing,says Reese Tisdale, the president and CEO of Bluefield Research, an independent advisory firm that aims to help companies and organizations address regulatory and business trends in the water sector. "We expect to know what we're ingesting and understand what the impacts are on ourselves and the environment."

Today, 120 Water Audit works with clients in 14 states, including four statewide contracts, and its software has been implemented on more than 175,000 taps, Glover says. The majority of the business is built on partnerships with water systems, while about a fourthgoes to state contracts, says Glover. However, she still receives a steady trickle of individual consumers seeking her water testing kits, but that makes up less than 1 percent of the company's revenue, Glover added.Prices vary depending on the customer's location and size of its water program, but the company's average contract value is just under $270,000 per year.Currently, Glover employs a team of 36 workers.

However, the startup still faces industry-specific challenges, like heavy regulation and a lack of funding from investors."It's not a technology problem, it's that there aren't enough dollars to go around," Tisdale says. "There is no white knight out there with bags of money to save your municipal water supply."

What's more, startups in the clean water space will face stiff competition from larger companies that offer diversified services and have the financials to withstand market changes or slow adoption rates, Tisdale says. Prominent U.S.-based heavyweightsinclude Xylem and Danaher, both of which are public companies that own multiple brands in the clean water space, he adds.

Glover is lookingto expand 120 Water Audit's reach by launching a commercial application later this year. The program would give safe drinking water certifications to establishments like hotels and restaurants.

As for the results of the water analysis in her own home, Glover was relieved to learn her tap water was safe. She says she wants to give many more people the same peace of mind. "Once you know a lot of this stuff, you can't unknow it."

Published on: Feb 4, 2020

Read more here:
This Founder Couldn't Find an Affordable Way to Test Drinking Water After the Flint Crisis, so She Created One - Inc.

When Malaysia Airlines Flight 370 disappeared on its way from Kuala Lumpurto Beijingin 2014, aerospace engineer Payam Banazadeh, then 23, fixated on one question: Why couldn't satellites scan the area where the plane disappeared in real-time?

"As I pulled the thread, what was very clear was that there was a huge gap in monitoring our planet from space," Banazadehsays.

Of thehundreds of schoolbus-size Earth-observation satellites currently in orbit, the majority use optical imaging, which typically can't see 75 percent of the Earth's surface because of weather issues and darkness, according to Banazadeh. At the same time, the cost of sending satellites into orbit is falling dramatically as governments and private companies launch a growing number of rockets into space, creating new opportunities for entrepreneurs to puteyes in the sky.

Banazadeh, a former project manager at NASA, saw a problem he could solve and the perfect moment to do it, so he founded Capella Space in 2016 with the goal of developing a smaller, more powerful satellite. In 2019, the company launched its first prototype satellite Denali, a backpack-size device that uses a technology called Synthetic Aperture Radar (SAR), which can see through clouds and at night.

In 2020, Capella will launch sevensatellites that togetherwill be able to monitor the entire surfaceofthe planeteverysix hours, on average, according to Banazadeh. The company will launch an additional sixto 12 satellites per year until it has 36 in orbit, at which point he says the time between updates will drop from up six hours to up to one hour. Capella will allow customers to submit requests for data and imagery through an automated system in a matter of minutes,16 times faster than rivalcompanies can, according to Banazadeh.

A wide range of applications

Unlike optical imaging satellites, which relyon incominglight to produce an image, Capella's satellites send a radar signalthat hits the Earth's surface and is reflected back to the satellite.The resulting data is used to produce an image that can detect changes tothe Earth's surfaceless than a meter in size. The structural integrity of a bridge, for example, can be monitored over time to determine whether maintenance workneeds to be done.

Although Capella's fleet of satellites isn't commercially operational yet,the companyhas already signed multimillion-dollar contracts with U.S. government agencies, including the U.S. Air Force and the Department of Defense's National Reconnaissance Office. "We will be monitoring certain spots for them and alerting them of any change," Banazadeh says.

The applications for Capella's servicesextendfar beyond providing information for governmentagencies.Banazadehsaysthe companyhas deals in place with private sector customers, thoughhe can't disclose their names.Being able to trackthe supply chain ofmajorcommodities like oil is onecapability hesays will create significant value.And because Capella's radar can also measurethe moisture levels of soil, monitoringthe health of crops for the agricultural industry represents another opportunity. Perhaps the most valuable service will beprovidinginformation tofirst responders during emergencies like storms, fires, andother natural disasters.

"The ability for us to immediately look through the clouds while the storm or disaster is happening, do damage assessment, and provide thatto the first responders to tell them what the best route is--those are the types of interactions we can start having," Banazadeh says.

Lower costs mean greater opportunity

With around 100 rocket launches taking place every year,the cost of sending satellitesinto space has fallen to between $20,000 and $40,000per kilogram. "It used to be that governments would launch these gigantic, billion-dollar satellites into space once every couple years," says Todd Dagres, a co-founder at Spark Capital, one of Capella's investors. "What's happened is, the bar has dropped so precipitously that countries that before could hardly get a train to run on time are pumping iron to the sky."

Elon Musk's SpaceXrecently began offering monthly missions to small satellite operators starting at $1 million, or$5,000 per kilogramfor up to 200 kilograms of payload mass.(In March, Capella's first operational satellite, called Sequoia, is scheduled tolaunch on a SpaceX Falcon 9 rocket from Cape Canaveral, Florida.) Theindustry also has benefited from lower costs for the components required to build small satellites. "A lot of that is driven by the commercial electronics industry--the stuff that is feeding the newest features on our iPhones and laptops,"says Mike Safyan, vice president of launch at Planet, an Earth-observation company that provides satellite imagery data. "That's being folded into the space industry in a way that hasn't really been done before."Capella declined to disclose how much it costs to buildits satellites.

Venture capital investment into space technology companies hasgrown to $2.27 billion in 2019 from $2.6 million in 2011, according to market data provider PitchBook.Capella has raised more than $80 million in funding, primarily from venture capital firms Data Collective andSpark Capital. The global nanosatellite and microsatellite marketis expected to grow to $3.6 billion by 2024 from $1.5 billion in 2019, according to research firm MarketsandMarkets.

Companies that provide satellite observation services similar to Capella's, albeit using much larger satellites, include multinational aerospace corporation Airbus and Italian company e-GEOS.Banazadeh says the value Capella brings is significantlydifferent from what these companies can offer thanks to its constellation that can repeatedly observe specific areas of the planet.

"They have these giant satellites that can do more things thanour satellites can do, but they can't really have the cadence at the cost that we can provide," he says. "I think we're very much complementary with those guys."One startup competitor isJapaneseSAR company Synspective, which raised $100 million in funding last July. Twoof the biggest challenges facing all satellite companies, according to Banazadeh,aresecuring reliable launch vehicles andputting satellites into orbit on time, asrockets are in high demand and launch delays are the norm rather than the exception.

In as soon as the next five years, Banazadehsays Capella's data could be useful for predicting future events, like where illegal fishingis likely to take place.

"If I were looking at that area from space using my satellite and combining it with other satellites and other data--this is the route they take and this is what the boat looks like--the next time I can start predicting who is doing what," he says. "As we start building this really dense data set of high quality and high cadence, that's going to be really interesting."

Published on: Feb 4, 2020

See the original post here:
An Ex-NASA Employee Is Launching Satellites Into Space to Predict the Future and Help Save Lives - Inc.

By Dr. Darrell Dantzler, faculty member, Emergency and Disaster Management at American Military University

On January 30, the World Health Organization (WHO) determined the novel coronavirus, formally known as 2019-nCoV, posed an international risk and declared it a Public Health Emergency of International Concern (PHEIC) and a global health emergency, a designation only declared five times previously.

The number of diagnosed 2019-nCoV cases has surpassed SARS cases, including the first known human-to-human spread of the new virus in the United States.

[Related: CDC to Announce First Case of Wuhan Coronavirus Found in US]

The Centers for Disease Control and Prevention (CDC) expects many more cases, largely due to the viruss ability to spread from person to person.

However, despite these designations and concerns from health experts, the 2019-nCoV is not classified as a pandemic; although that is subject to change based on the rate of human-to-human transmissions and determination of the lethality of the virus.

[Related: Flu Season and Pandemic Planning: Ethical Approaches to Epidemic Response]

It is critical that state, local, tribal, and territorial (SLTT) emergency managers, public health professionals, and other public safety professionals understand global and national comprehensive emergency management strategies for handling a pandemic outbreak. They include how these strategies affect them and their SLTT emergency management initiatives.

The WHOs primary role is to direct and coordinate international health within the United Nations system. The WHOs goals during the 2019-nCoV outbreak are to strengthen global diagnostic capacity and improve surveillance, early detection, and capabilities to track the spread of disease. WHO lists the following six strategic objectives for responding to the 2019-nCoV:

WHO has implemented a three-pronged approach to enhance the diagnostic capacity for 2019-nCoV:

The U.S. Department of Health and Human Services (HHS) mission is to enhance and protect the health and well-being of Americans by providing effective health and human services and by fostering advances in medicine, public health, and social services. The secretary of HHS is vested with the authority to act to protect public health and welfare, declare a public health emergency, and prepare for and respond to public health emergencies. The CDC, within the HHS, is the nations health protection agency and the leading national public health institute in the country.

HHS developed seven domains in its Pandemic Influenza Plan to thwart a severe worldwide event. Although 2019-nCoV has not reached the pandemic threshold yet, its important to understand the Pandemic Influenza Plans seven domains, which details areas where capabilities can be optimized:

Regarding the 2019-nCoV, the CDC has accomplished the following strategic response objectives:

At this point, most SLTTs have reviewed and put into place their comprehensive emergency management plan, including the Pandemic annex and the Emergency Support Functions (ESF), including ESF #8, as well as companion ESFs.

SLTT public safety professionals should monitor the global and national climate, along with maintaining situational awareness in their jurisdiction. The director of the HHS stated, (t)he playbook for responding to an infectious disease outbreak is relatively simple: You monitor and communicate, identify cases, isolate the people, diagnose them, and treat them. Then you track down all of the contacts of the infected person, and you do the same with those people, and the same with contacts of contacts if necessary. This is often easier said than done, as virus outbreaks foster volatile, uncertain, complex, and ambiguous (VUCA) environments that require immense coordination. Communication and social distancing are among challenges that SLTT public safety official encounter.

Communication

The goal of communication before, during, and after VUCA events like 2019-nCoV is to provide and share accurate and relevant information with the public, partners, and stakeholders, so that well-informed decisions are made that protect the publics health and safety.

Social medial is a double-edged sword when communicating during disease outbreaks. Currently, hoaxes about the coronavirus have spread faster than the actual virus on platforms like Facebook, YouTube, and Twitter. Some examples include Bill Gates being responsible for the virus; the Chinese created a weaponized version of coronavirus and lost control of it; drinking bleach keeps the virus away; coronavirus will cause the zombie apocalypse; parents have abandoned their children in an airport; FEMA proposes martial law to contain the coronavirus; and the US patented a vaccine years ago for the coronavirus.

Misinformation about disease outbreaks is even harder to control because of intense public interest, fear, lack of credible information, and the unknown. The WHO has actively sought to discredit misinformation and has responded to rumors through myth busting on WHOs social media channels and website.

The CDC indicated that the right message at the right time from the right person can save lives. The health agency implemented a six-step crisis communication plan that SLTT public safety agencies can employ to improve communication:

Social Distancing

If a 2019-nCoV outbreak is found in a SLTT jurisdiction, public safety managers can mitigate person-to-person transmission through social distancing. Social distancing is when public health officials restrict when and where people can congregate in order to stop or slow down the spread of a highly contagious. These social distancing measures have a considerable effect on the community; therefore, actions must be coordinated among all stakeholders including city leaders, federal partners, police departments, business, and schools.

Below are some examples of social distancing that can be used to control the spread of 2019-nCoV. Its important for SLTT emergency managers to remember that civil liberties must be balanced with public health.

In summary, the global and national strategies for controlling and eradicating pandemics or the 2019-nCoV directly impacts the strategies at the SLTT jurisdictional levels. Public safety officials should understand the global and national climate to better prepare for, respond to, mitigate, and recover from a potential pandemic in their jurisdiction.

Additionally, SLTT public safety officials must understand crisis communication and ensure their jurisdictions have the most updated and accurate information. Lastly, when determining social distancing strategies, civil liberties must be balance with public health.

About the Author: Dr. Darrell Dantzler is a faculty member at American Military University, teaching courses in Emergency & Disaster Management. He is also the Director of the Fire Protection Analysis and Field Engineering Division within the Office of Fire Protection in the Bureau of Overseas Buildings Operations at the US Department of State. Darrell brings more than 35 years of experience in Disaster and Emergency Management Planning and Response. He is a 20-year United States Air Force Veteran and a 15-year public servant with the Department of State. At State, he conducted fire assessments, fire investigations, and special emergency management assessments in over 70 countries. Darrell graduated from the National Preparedness on Leadership Initiative, Executive Education Leadership Program at Harvard Universitys T.H. Chan School of Public Health and Harvards Kennedy School of Government. He is a Certified Emergency Manager through the International Association of Emergency Managers. Darrell holds a Ph.D. in Public Safety Leadership with a specialization in Disaster and Emergency Management. To contact the author, email IPSauthor@apus.edu. For more articles featuring insight from industry experts, subscribe to In Public Safetys bi-monthly newsletter.

Sign up now to receive the InPublicSafety eNewsletter.

See the rest here:
Impact of Global and National Coronavirus Strategy on the SLTT Response - In Public Safety

Gerald R. Fink,Whitehead Institute founding member and former director and professor of molecular genetics in the MIT Department of Biology, has been awarded the 2020 Thomas Hunt Morgan Medal, bestowed by the Genetics Society of America (GSA). The award recognizes a distinguished scientist who has a lifetime achievement in the field of genetics and a strong history as a mentor to fellow geneticists. TheGSA is an international community of more than 5,000 scientists who advance the field of genetics.

Fink, who is also the Herman and Margaret Sokol Professor at Whitehead Institute, is a former GSA president and the 1982 recipient of the GSA Medal. In honoring him with the Thomas Hunt Morgan Medal, GSA is recognizing Finks discovery of principles central to genome organization and regulation in eukaryotic cells.

This year, the Morgan Medal will also be awarded to David Botstein, chief scientific officer for Calico Labs and professor emeritus of molecular biology at the Lewis-Sigler Institute for Integrative Genomics at Princeton University, in recognition of his multiple contributions to genetics, including the collaborative development of methods for defining genetic pathways, mapping genomes, and analyzing gene expression.

These awards to Gerry and David are richly deserved and I am so pleased they are being honored together, says Whitehead Institute DirectorDavid Page. Gerry Fink has fundamentally changed the way researchers approach biological problems, and his many discoveries have significantly shaped modern science. David Botstein has helped drive modern genetics, establishing the ground rules for human genetic mapping. Page has worked closely with both men: beginning his research career as an investigator in Botsteins lab, and collaborating with Fink for more than three decades at Whitehead Institute.

The medals will be formally presented to Fink and Botstein at the Allied Genetics Conference in April.

More here:
Gerald Fink awarded the Genetic Society of America's Thomas Hunt Morgan Medal - MIT News

Researchers shed new light on the genetic relationship between three mood disorders associated with depressionmajor depression and bipolar disorder types 1 and 2, in a newstudyin the journalBiological Psychiatry, published by Elsevier.

The clearest findings are a genetic distinction between type 1 bipolar and type 2 bipolar, and the greater similarity of type 2 bipolar to major depressive disorder, said first author Jonathan Coleman, PhD, a statistical geneticist and postdoctoral fellow in the lab of senior author Gerome Breen, PhD at the Institute of Psychiatry, Neuroscience, and Psychology at Kings College London, UK.

Both types of bipolar disorder used to be referred to as manic-depressive disorder. Mania is a behavioral state associated with behavioral activation, euphoric or irritable mood, reduced need for sleep, impulsive behavior, impaired judgement, racing disorganized thoughts, impulsive behaviors, and frequently strongly held false beliefs (delusions) or hallucinations. Bipolar disorder type 1 is associated with mania and depression, while bipolar 2 is predominately associated with depression marked by mild symptoms reminiscent of mania, called hypomania.

The insights came from several extremely large datasets analyzed together. For their meta-analysis, Coleman, Breen and their co-authors combined genome-wide association studies from three large datasets of people with major depression and bipolar disorder to evaluate shared and distinct molecular genetic associations. Most of the data came from the large international Psychiatric Genomics Consortium. Additional data came from the UK Biobank, a major health resource established by the Wellcome Trust, and the online genetic service platform, 23andMe.

There are significant racial and ethnic differences in the findings from genome-wide association studies (GWAS). The findings of this study pertain only to people of European ancestry and findings might be different in other groups.

The authors also report that the genetic risk for these disorders was predictive of other traits as well. For example, the genetic risk for bipolar disorder was correlated with more educational attainment, while the heritable risk for major depressive disorder was associated with less education.

In the mouse brain, the authors also mapped the genetic risk for these disorders on to particular brain cell types using a sophisticated analytic strategy building on the pattern of genes expressed. They implicated serotonin neurons in the risk for both depression and bipolar disorder, while bipolar disorder distinctively involved GABA and glutamate neurons (nerve cell types also implicated in schizophrenia).

We have long known that mood disorders are highly heterogeneous and the boundaries between types of mood disorders are often difficult to define clinically, said John Krystal, MD, editor ofBiological Psychiatry. This new study suggests that there are aspects of genetic risk, and presumably brain function, that link forms of mood disorders, but there are also distinctions that may shed light on subtypes of depression that may have important implications for treatment.

Ultimately, the researchers want to develop clinical tools to help predict if a first episode of depression is likely to persist as a disorder or progress into bipolar disorder. Genetic data wont ever replace clinical insight, but it might be a useful addition to clinical models, said Coleman.

Reference:Coleman et al. (2019). The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. Biological Psychiatry. DOI: 10.1016/j.biopsych.2019.10.015.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post here:
New Light on the Genetic Relationship Between Three Mood Disorders - Technology Networks

The following is a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks that hit 52-week highsFeb. 5.)

Down In The Dumps

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Stocks In Focus Sanofi's Multiple Sclerosis Drug Aces Midstage Trial; Q4 Sales, Net Income Rise

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix To Stop Enrollment For Late-Stage Study Of PTSD Drug

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Reports Positive Mid-Phase Results For 2 Cardiometabolic Drug Candidates

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Earnings

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

View more earnings on IBB

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Offerings

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

On The Radar Clinical Readouts

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Earnings

IPO

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

0

See more from Benzinga

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Visit link:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Yahoo Finance

A multicentre study across 18 centres finds 10kHz safe and effective for the treatment of painful diabetic neuropathy. Sensory improvements were observed in many patients who underwent stimulation with these parameters, as well improvements in quality of life measures. Erika Petersen, University of Arkansas for Medical Sciences, Little Rock, USA, presented these data at the North American Neuromodulation Societys (NANS) annual meeting (2326 January, Las Vegas, USA) and told delegates that the study is due to run through 24 months, with later evaluations of health economics and pain medication usage.

Our clinical trial is the largest randomised controlled trial to date, involving 216 patients randomised 1:1 to conventional medical management [n=103] alone or conventional medical management plus high frequency 10kHz stimulation [n=113], explained Petersen.

She added that all patients were evaluated by independent medical monitors before they were enrolled in study, and were required to have at least 5 of 10cm of the visual analogue scale (VAS) as well as a BMI <45 to be included. When looking at the demographics of the two arms, Petersen said, they are identical; no significant differences were observed in terms of duration of diabetes, duration of time of painful diabetic neuropathy, gender, and other factors.

Lead location was T8T11. Petersen posited that this is the typical location for addressing lower limb and lower extremity pain. She further emphasised that one of the endpoints of the study was safety. For the stimulation group, 19 adverse events [occurred] in 15 patients, two of which were rated as a serious adverse event, she acknowledged, adding that one arose due to infection, while the other was acquired at plantation.

I want to highlight our infection rate, Petersen said. People worry about diabetics having a higher risk of infection. But, what we can see for this population, is a 1.8% rate, which is comparable to the majority of studies in the literature for this population.

For the primary endpoint analysis, Petersen and her co-investigators looked at a composite of safety and effectiveness, in terms of pain reduction at three months. Those with 50% pain relief without a worsening neurological deficit from baseline were characterised at responders. Of the patients receiving SCS stimulation, 86% were considered responders at three months, compared to only 5% of patients in the conventional medicine management arm, reported Petersen, adding that the team observed a trial stimulation success rate of 94%.

She alluded to the reduction in VAS scores, which decreased from 7.6 (lower limb VAS) at baseline to 2.4 at one month, and 1.7 at three months. I hope to be able to show you think maintained at 24 months when we present those data in the future, Petersen noted. Moreover, through looking at individual pain relief between the stimulator and the conventional management group, it was revealed that 77% of stimulation patients achieved pain relief, compared to only 5% of controls.

Part of the assessment was to have each investigator assess sensory changes within the patients, Petersen explained. The team had asked patients to draw out subjective diagrams of where they perceived numbness, both at baseline and three months. We were able to perceive what seemed to be a change in sensation in the stimulator population in 72% of those patients, Petersen confirmed.

But pain relief is nothing without improving quality of life, said Petersen, alluding to the fact that investigators examined three measures of sleep, each of which saw significant improvements. They also implemented a six-minute walking test as a means of achieving an objective measure of functional improvement. Compared to the conventional medical management group, the stimulator patients walked further in six minutes at the three-month time point. When you look at this by individuals, Petersen discussed, you can see that it is not across all patients, but the average and median change allows for a longer distance walked [of 39 metres; a 17% increase] in the same amount of time.

In terms of impression of change, both patients themselves as well as the clinicians evaluating them were asked to assess their improvement. In total, 67% of the stimulator population said they are better/a great deal better than baseline, compared to a mere 2% of controls. These findings were reflected throughout a multitude of other functional indicator questionnaires, noted Petersen.

Read the rest here:
News from NANS: 10kHz safe and effective for treating painful diabetic neuropathy, multicentre study finds - NeuroNews International

Waldenstrm macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma that mainly affects elderly patients. Complications of the disease are usually attributable to tumor load or the presence of monoclonal immunoglobulin M (IgM). With limited approved treatment options by the US Food and Drug Administration (FDA), the demand for new therapies is high.

In a review published in Blood, Meletios A Dimopoulos, MD, and Efstathios Kastritis, MD, of the department of clinical therapeutics at the University of Athens in Greece, summarized current literature surrounding the treatment of WM.1 They also reviewed several example cases using clinical data from their institution.

Diagnostic Workup and Indication for Therapy

If the presence of IgM is confirmed by immunofixation electrophoresis, and a bone marrow biopsy reveals infiltration with clonal lymphoplasmacytic cells, a diagnosis of WM is established. Indolent cases are defined as those with less than 10% clonal infiltrate, but there is no established threshold for the amount of clonal cell infiltrate required for diagnosis. Although variation in clonal morphology is high, established cell morphology and immunophenotypic criteria aid in differential diagnosis among other conditions that exhibit a similar phenotype.1

During the initial workup, ruling out other causes of presenting symptoms is important. At initial presentation, the most common symptoms are anemia and cytopenias (42%), B symptoms (25%), and hyperviscosity (17%). As a result, additional laboratory parameters should be measured, including iron studies, serum albumin, lactate dehydrogenase, and beta-2 microglobulin. The measurement of monoclonal IgM levels is also necessary, as hyperviscosity syndrome, a key marker of symptomatic disease, is related to elevated IgM levels; however, this relationship is not linear.1

Another common complication of the disease is peripheral neuropathy, which in many cases is the sole indication for treatment in asymptomatic patients. WM-associated neuropathy is often slowly progressing, sensory, and symmetrical in nature. Hence, rapidly progressing peripheral neuropathy may indicate an unrelated cause.

Because of a prolonged asymptomatic period, often exceeding 5 to 10 years, it is crucial to ensure patients have an indication for therapy. Though some clinical and laboratory indications have been proposed, clinical judgment is often necessary. Monoclonal IgM levels alone are insufficient to determine an indication for therapy. Currently, there are no data to help guide clinical decision making on whether to delay or commence therapy in asymptomatic patients. In these cases, enrollment into a clinical trial may be a suitable option.

Originally posted here:
Current and Prospective Treatment Options for Waldenstrm Macroglobulinemia - Hematology Advisor

Cancer has an impact on every part of a patient's life. At GBMC Healthcare, the fight against cancer is about more than treating the disease. Delia Chiaramonte, M.D., Medical Director of Integrative and Palliative Medicine at GBMC, is leading the charge on integrative cancer care.

"It's not just about treating the cancer. It's also about how the person is coping, what side effects they may have from the disease itself or from the treatment, and how those symptoms make their life harder to manage," she says. "Treating the whole person is a really important part of cancer care."

These symptoms can be caused by a variety of internal and external sources, and Dr. Chiaramonte says it's important to get to the root of the cause of the symptom to better treat the patient.

"We hear the patient's symptoms then make an evidence-supported treatment plan that's different for every person, based on what their symptom is and why we think their symptom is happening," she explains.

For example, one person may not be sleeping well because of a physical reaction to chemotherapy. Another may not be getting good sleep because their mind is filled with anxious thoughts about their diagnosis.

Dr. Chiaramonte says there are three main causes of symptoms, and the Integrative Medicine Program makes it easier for patients to get an evidence-based, effective treatment plan and to receive those treatments at the Sandra & Malcolm Berman Cancer Institute at GBMC.

"We pull out all the causes and then address them with the treatment that is likely to work on that particular person, and often it's not just one cause," she explains.

The mind-body connection

The sympathetic nervous system directs our body's "fight or flight" response, which can be caused by both external factors and our own thoughts.

"Because the mind and body are connected, our anxious thinking can generate the 'fight-or-flight' response, and that can result in all kinds of physical symptoms, including increased pain, palpitations, changes in GI function, sleep, and nausea," Dr. Chiaramonte says.

According to Dr. Chiaramonte, there are a variety of ways to help decrease the sympathetic nervous response system, including craniosacral therapy (a light-touch manual therapy technique that works to balance and facilitate healing in the body) and massage. These methods reduce patients' anxiety.

Cancer treatment symptoms

It's no secret that chemotherapy and radiation can be taxing on the body. Nausea, fatigue, and neuropathy (nerve pain caused by damaged nerves) are just some of the side effects of cancer treatments that integrative modalities can help alleviate.

"Some energy medicine has been shown to help chemo-induced peripheral neuropathy," Dr. Chiaramonte says. "Many people come in with fatigue, usually from a combination of poor sleep and treatments. Acupuncture, meditation and guided imagery, reiki (a stress reduction and relaxation technique involving a trained practitioner), and yoga have all been shown to help fatigue."

Physical pain

Dr. Chiaramonte reiterates that the Integrative Palliative Medicine Program is just that: an integrative medicine program and not an alternative to standardized cancer care.

"I treat pain with medicines, with different kinds of opiates and complementary medications," she says. "But acupuncture has been shown to decrease pain. Meditation and guided imagery have been shown to decrease pain. Reiki has been shown to decrease pain. Depending on the person, we may use multiple modalities to help them manage their pain."

Massage is also an oft-used modality for physical pain.

"Often, when something hurts in our body, the muscles around it contract and tighten to try to protect it, and over time it can become the actual contraction of the muscle that hurts, not necessarily the underlying factor," Dr. Chiaramonte says.

She explains this can also tie into the mind-body connection because "if you're generating a lot of anxious thinking, you're more likely to continue to have this muscle tension, and massage can help."

Integrative treatment plans will vary by patient, which Dr. Chiaramonte says is the key to taking care of the mind, body, and spirit of every individual.

"We find out the 'why' behind each patient's symptoms, pull out the causes, and then come up with a plan for that particular patient, using all the tools that work."

For more information Integrative Medicine at GBMC HealthCare, click here.

Read this article:
How integrative medicine is changing the way cancer is treated - Fox Baltimore

VertexMarketInsights.com has published an innovative statistics of the market titled as Neuropathy Pain Treatment Market. To clarify the various aspects, the analyst studies and elaborates the terms by using qualitative and quantitative research techniques. Finance teams can use a variety of corporate planning applications to fulfil the budgeting, planning & financial modelling, needs of their organization, whatever its size, industry and location.

Graphs, tables, bar graphs and pie charts have been represented in sophisticate manner for the clients to better understand the analysis. To enlarge the businesses, customers get increased rapidly through Neuropathy Pain Treatment industry techniques.

Download Exclusive Sample of Neuropathy Pain Treatment Markets Premium Report @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #request-sample

Leading Establishments (Key Companies):PfizerDepomedEndoGrnenthal GroupArbor PharmaceuticalsEli Lilly

Different regions, such as Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey and GCC Countries are focused to give the summarized data about the production of Neuropathy Pain Treatment market.

The global Neuropathy Pain Treatment Market is served as a backbone for the enlargement of the enterprises. To address the challenges, the report examines different key factors such as drivers and opportunities. Restraints are considered for evaluation of risk in market.

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and analyses the market trends in each of the sub-segments from 2015 to 2025. For the purpose of this study, VertexMarketInsights have segmented the Neuropathy Pain Treatment market on the basis of type, end-user and region:

Type Outlook (Revenue in Million USD; 20152025):Calcium channel alpha 2-delta ligandsSerotonin-norepinephrine reuptake inhibitors

End Use Outlook (Revenue in Million USD; 20152025):Retail PharmaciesHospitals

Neuropathy Pain Treatment Market Summary: This report includes the estimation of market size for value (million US$) and volume. Estimation methodology validate the market size of Neuropathy Pain Treatment industry, to estimate the size of various other dependent submarkets in the overall market. Secondary research is used to identify the top players in the market, and their market shares have been determined through primary and secondary research. Each type is studied based on classification as Sales, Neuropathy Pain Treatment Market Share (%), Revenue (Million USD), Price and Gross Margin.

If You Have Any Query, Ask Our Experts @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #inquiry-before-buying

Report Objectives:

Target Audience:

Table of Content:

Global Neuropathy Pain Treatment Market Research Report 2020-2025

Chapter 1: Industry Overview

Chapter 2: Neuropathy Pain Treatment Market International and China Market Analysis

Chapter 3: Environment Analysis of Market.

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Neuropathy Pain Treatment Market Revenue Market Status.

Chapter 7: Analysis of Industry Key Manufacturers

Chapter 8: Conclusion of the Neuropathy Pain Treatment Market Industry 2025 Market Research Report.

Continued to TOC

For more detailed Pdf Copy of Table of Content Describing Current Value and Volume of the Market with All Other Essential Information click @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #table-of-contents

****Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

Tags: Global Neuropathy Pain Treatment IndustryGlobal Neuropathy Pain Treatment MarketGlobal Neuropathy Pain Treatment Market growthGlobal Neuropathy Pain Treatment Market ShareNeuropathy Pain Treatment

View original post here:
Neuropathy Pain Treatment Market 2020 Industry Sahre, Growth, Top Manufacturers, Globally Development and Forecast to 2025 - TechNews.mobi

After facing months of rehab due to injury, pole vaulters Arielle Sclar 22 and Lulu Knowles 21 recently returned to the track and field team with the support of their teammates, coaching staff, and the sports medicine department.

In the winter of my senior year of high school I was at a pole vault meet, and I landed poorly and tore my ACL and meniscus, Sclar said. I waited the full year to come back which is protocol for ACL surgery, and then there were complications, and I had a second surgery at the start of [the] fall [2019] semester.

Sclar said that it was difficult getting back into pole vaulting after her knee injury since she was not able to do any cardio exercises during rehab. She described her recovery process as long and intensive, but noted the consistent support from her teammates.

Ive never felt disconnected from the team, she said, despite being out for most of last season.

Knowles was injured at the end of her freshman year. Her injuries led her to switch from triple jump to pole vault.

I shattered my kneecap when I was still a triple jumper, she said. I really wanted to be part of the team, and since I was a gymnast, my coach asked if I would pole vault. Sophomore year I had ulnar neuropathy, which I trained and competed through for a while, but then it got really dangerous and I had to get surgery. Ulnar neuropathy, according to Medical News Today, affects the nerve the runs along the arm along the elbow and into the fingers on the outside of the hand.

Track and field head coach Michele Curcio witnessed their recovery and said that they really embraced their rehab.

Sports medicine did a great job of making sure they were ready, Curcio said. Sometimes the student athlete gets ahead of themselves. As an athlete, you think youre going to be able to do things quicker than the normal person.

Both athletes added that not being able to physically participate on the team was challenging at times.

Sometimes its really frustrating watching people do the sport you love when you cannot take part in it, Knowles said. I had contemplated just quitting, I had so many injuries. But sitting out made me realize how much I loved being part of a team and competing. Pole vault definitely gives me that thrill that I love and being out made me love the sport even more.

Its not a great feeling watching everyone else be healthy and doing what you wish you could be doing, Sclar added. But it was easier for me when thinking of how exciting it would be to be back.

While Knowles suffered her injury in a different field event, returning to the same exercise that initially caused the injury, as was the case with Sclar, presented an additional obstacle to their recovery.

The hardest thing is to come back [and] to do that thing that made you hurt, Curcio said. You have to bring them back slowly and break that mental barrier.

The support and positive energy of their teammates played a big role in their recovery and mental toughness.

Every team member here appreciates each other and being on the team, and a lot of them have gone through the same things, so I think that type of support before and after [an injury] is important, Curcio said.

Both Knowles and Sclar are now back with the team and competed last weekend at the DeSchriver Invitational. Knowles and Sclar placed fifth and sixth, respectively, in the pole vault with marks of 2.90 and 2.75 meters. Being back with the team full-time is already having an impact on both women.

People dont recognize how many things go on to make the whole track team be functional and do well, Sclar said. Everyones coming from a very different place to make a common goal as a team unit.

I love our team dynamic, especially this year because we have some freshman who joined and brought great positive energy, Knowles added. Everyone has a different major and a different story, you just get to talk to so many different people.

Knowles, Sclar and the rest of the track and field team return to action today at the University of Albany winter classic in Staten Island, N.Y.

Read the original:
On the track to recovery: Pole vaulters talk about their returns from injuries - The Lafayette